Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: jpgetty who wrote (235)	2/26/1998 9:00:00 AM
From: BDR	Respond to of 384

From the MB thread: Just found at Investors Business Daily online (in Nasdaq daily review article): "Sonus Pharmaceuticals lost 6 5/8 to 28 7/8 on almost triple its average volume. Analyst David Crossen of NationsBanc Montgomery Securities warned clients that FDA approval of the company's contrast agent is not assured. There may be manufacturing- related problems, he expects, though the company did not give him specifics. He says the FDA will issue an ''action letter'' Thursday. The stock is 38% off its October high." If this proves true, why is Sonus management only telling this information to this one analyst and not returning calls from investors to IR?